Antipsychotic Polypharmacy: Prevalence, Background and Consequences

Study Overview
=================
Brief Summary
-----------------
The primary purpose of the study is to investigate whether an intensive educational intervention can reduce the use of antipsychotic polypharmacy. It is hypothesised that the use of antipsychotic polypharmacy is, in some degree, dependent on non-patient related factors.

Detailed Description
-----------------
Several surveys have shown a high prevalence of antipsychotic polypharmacy (concomitant prescription of at least 2 different antipsychotics) among patients with schizophrenia even though international guidelines recommend monotherapy. From register data areas with differences in the prevalence of antipsychotic polypharmacy will be identified. Two high prevalence areas will be randomized to either control or intervention area. In the intervention area an intensive educational intervention consisting of outreach visits with a multifaceted approach will be carried out with the duration of 1 year. Differences in health staff related factors such as knowledge and attitude towards clinical guidelines will be assessed with a questionnaire before and after the intervention in the intervention area as well as in the low prevalence area at baseline. Medical records data describing the use of antipsychotic polypharmacy will be collected. With register data health economic issues will be assessed.

Official Title
-----------------
Antipsychotic Polypharmacy: Prevalence, Background and Consequences

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Behavioral: Implementation of guideline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The intervention is not aimed directly to the patients but their health care providers. Patients with schizophrenia (F2* diagnosis according to ICD-10) taking antipsychotic medication and their health care providers in the specified areas will enter the study: The patients will enter with data from their medical record, register data and a few exploring interviews while the health staff will enter with their questionnaire data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Behavioral: Implementation of guideline<br>* Outreach visits with interactive education for health staff<br>|
| No Intervention: B<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of antipsychotic polypharmacy |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire assessment of non-patient related factors. Medical records data. Cost-effectiveness analysis. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antipsychotic polypharmacy, Schizophrenia, Implementation of clinical guidelines